Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma

Learn more about:
Related Clinical Trial
Cell-free Tumor DNA in Head and Neck Cancer Patients Exploring the Application Value of PET Molecular Imaging Targeting FAP in Oral Squamous Cell Carcinoma Exfoliated Cytology in Detection of Oral Premalignant and Malignant Lesions The Oral Microbiome in OSCC The Link Between Periodontitis, Smoking and Oral Cancer Research on Optimization and Evaluation of Oral Cancer Screening Methods Low-Cost, Portable Flexible Nasopharyngoscope in Head & Neck Cancers in Low Resource Settings Topical Aldara (Imiquimod) for Oral Cancer Diagnostic Accuracy of Salivary Gamma-synuclein in Oral Malignant and Premalignant Lesions LLL Phototherapy in Oral Lesions Resulting From Anti-neoplastic Treatment Enhancing Self Care Among Oral Cancer Survivors: The Empowered Survival Trial Understanding Non-radiotherapy-based Development of Trismus Use of Ultrasound for Measuring Size of Oral Tongue Cancers Green Tea Mouthwash on the Oral Health Status in Oral Cancer Patients Oral Cancer Screening and Education in Hong Kong Evaluating Oral Visual Inspection in the Control of Oral Cancer Inductive Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients Effects of EMG Visual Feedback for Spinal Accessory Nerve Dysfunction After Neck Dissection: a Randomized Clinical Trial Prevention of Oral DNA Damage by Black Raspberries Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma NBI in Oral Cavity Cancer Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer Physical Activities by Technology Help (PATH) Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC Role of Neo-adjuvant Chemotherapy in Tongue Preservation in Locally Advanced Squamous Cell Carcinoma of Oral Tongue Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients Patient Evaluation for Head and Neck Surgery Branch Studies Complete Decongestive Therapy (CDT) for Treatment of Head and Neck Lymphedema Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer Quality of Life in Patients Treated for Tongue and/or Jaw Neoplasia Before and After Speech Therapy Prospective Analysis of Robot-Assisted Surgery Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery Extended Follow-Up of Young Women in Costa Rica Who Received Vaccination Against Human Papillomavirus Types 16 and 18 and Unvaccinated Controls Clinical Evaluation of the OncAlert RAPID in Subjects Presenting for Evaluation and/or Initial Biopsy; Impact on Decision-Making Neo-adjuvant Erbitux-based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer Cigarette Smoking and Oral Microbiota Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma Therapeutic Effect Of Luteolin Natural Extract Versus Its Nanoparticles On Tongue Squamous Cell Carcinoma Cell Line The Role of Lymphangiogenesis in Head and Neck Cancer Metastasis Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis. MSOT Using Cetuximab-800CW for Detection of Cervical Lymph Node Metastases Oral Care Protocol for the Management of Chemotherapy and Radiation Therapy-Induced Oral Mucositis Least Invasive Nonlinear Light Microscopy Study of Induction Docetaxel, Cisplatin and 5-Fluorouracil Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN Trismus Trial of Therabite vs Wooden Spatula in Head and Neck Cancer Patients Improving Access to Control of Diseases for Women IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC Submandibular Gland Preservation in Neck Dissection uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer Postoperative Radiotherapy According to Molecular Analysis of Surgical Margins of Oral and Oropharyngeal SCC Autofluorescence Detection of Oral Malignancies and Database and Biospecimen Collection to Identify Biomarkers of Head and Neck Tumor Progression The Use of Functional Confections in Promoting Oral Health The Oral Microbiome and Upper Aerodigestive Squamous Cell Cancer A Study of Neoadjuvant Bio-C/T Followed by Concurrent Bio-R/T in High-risk Locally Advanced Oral Squamous Cell Carcinoma The Study of p62/SQSTM1 as a Malignant Transformation Marker for Oral Potentially Malignant Disorders and a Prognostic Marker for Oral Squamous Cell Carcinoma Evaluation of the Photobiomodulation Using LED Lamp for Curative Treatment of Radio-induced Mucositis. Spectroscopy for Diagnostic Assessment of Oral Mucosal Lesions Wild Type p53 Adenovirus for Oral Premalignancies Acupuncture Effect on Digestion in Critically Ill Post-Operative Oral and Hypo-pharyngeal Cancer Patients Cancer Chemoprevention by Metformin Hydrochloride in Oral Potentially Malignant Lesions Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions Trial of IIb Preserving Neck Dissection Expression of Hypoxia-Inducible Factor-α in Oral Precancers and Cancers Diagnosis of Oral Precancers and Cancers Using Optic Coherence Tomography Innovative Approach to Triage Oral Precancer The Role of SDF-1/CXCR4 in Metastasis of Oral Squamous Cell Carcinoma Rehabilitation Outcomes in Head and Neck Survivors Evaluation of a Multispectral Vision Enhancement System for Assessment of Oral Mucosal Lesions The Relation of Microtubule-Associated Protein 2 and Cell Migration Sensitivity and Specificity of Serum and Salivary CYFRA21-1 in the Detection of Malignant Transformation in Oral Potentially Malignant Mucosal Lesions (Diagnostic Accuracy Study) Prosthesis Guided Speech Rehabilitation of T1/T2 Cancers of the Tongue Oral Pathology Asynchronous Telementoring Pilot Study Polarized Reflectance Spectroscopy for Oral Lesions A Study of the Effects of PEITC on Oral Cells With Mutant p53 Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions Analysis of the Variation in Caspase-8 Availability and Cleavage in Oral Squamous Cell Carcinoma The Role of microRNA-29b in the Oral Squamous Cell Carcinoma Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer – COOLS TRIAL Assessment of Mandibular Bone Invasion With MRI Using SWIFT Effect of FDG-PET/CT for Simulation and Radiation Treatment Planning in Oral Cancer Patients Epstein-Barr Detection in Oral Cancer Workplace Tobacco Cessation And Oral Cancer Screening Study Low-cost Enabling Technology for Image-guided Photodynamic Therapy (PDT) of Oral Cancer Cancer. Elective vs Therapeutic Neck Dissection in Treatment of Early Node Negative Squamous Carcinoma of Oral Cavity Personalized Survivor Care Plan for Oral Cancer Patients-Effects on Physical-Psychological Functions and Return-to-Work Dental Hygienists and Dentists as Providers of Oral Mucosa Screening and Brush Biopsies Effects of Mouth-opening Training on the Maximum Interincisal Opening Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer Oral State of Patients Affected by an Oral Cancer Before and After Radiotherapy – 3-years Prospective Study Erlotinib Prevention of Oral Cancer (EPOC) Oral Cancer Screening in Mumbai, India by Primary Health Care Workers Study on the Carcinogenesis of Gα12 in Oral Cancer, and the Treatment of Oral Cancer Using Ga12 Inhibitor. The Optimal Neck Treatments Strategy of Early Oral Cancer Based on Adverse Pathological Factor Study on the Carcinogenesis of SOX-9 in Oral Cancer, and Chemopreventive Possibility for the Treatment of Oral Cancer. Validation of DNA Methylation Biomarkers for Oral Cancer Detection Validation of DNA Methylation Biomarkers for Oral Cancer Detection-Follow up Study Rehabilitation Outcomes of Shoulder Function in Oral Cancer Survivors Cancer Survivors Behavior Change on Oral Cancer Patients After a Localized Behavior Change Model Intervention Expression of VEGF-C and VEGF-CR in Oral Cancers and Premalignant Lesions PET/CT and Sentinel Node in Oral Cancer Validation of DNA Methylation Biomarkers for Oral Cancer Detection Web-based Education on Oral Cancer for Primary Care Physicians in Ohio Analysis Of Sensory Recovery Of Donor Size And Quality Life In Oral Cancer Patients Using an APP in Post Oral Cancer Surgery to Affect Patients’ Needs and Quality of Life.

Brief Title

Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma

Official Title

A Pilot Trial Targeting mTOR as a Novel Mechanism-Based Neoadjuvant Therapy for Head and Neck Cancer

Brief Summary

      Background:

      - Advanced-stage head and neck cancer (head and neck squamous cell carcinoma [HNSCC]) has
      moderately successful treatment outcomes, usually involving surgery as part of the standard
      treatment. Researchers are investigating the use of the drug rapamycin to prevent tumor
      growth in HNSCC, and are interested in using it to treat individuals with HNSCC that has not
      been treated previously with other drugs, radiation, or surgery.

      Objectives:

      - To evaluate the usefulness of rapamycin in decreasing tumor size prior to surgery for head
      and neck squamous cell carcinoma.

      Eligibility:

      - Individuals at least 18 years of age who have been diagnosed with advanced head and neck
      squamous cell carcinoma that has not yet been treated.

      Design:

        -  Participants will be screened with a physical examination, medical history, blood tests,
           and imaging studies.

        -  Approximately 1 month before scheduled surgery, participants will begin to receive
           rapamycin. Participants will take rapamycin once daily for 21 days, followed by a 7-day
           period without the drug.

        -  During the 21-day rapamycin treatment, participants will have weekly study visits to
           provide blood and urine samples and have possible tumor biopsies and imaging studies
           such as x-rays or tumor photographs. Participants will have additional study visits for
           tests 1 day and 1 week after the end of rapamycin treatment, followed by HNSCC surgery.

        -  Participants will have a final visit to provide blood samples 30 days after surgery.

        -  Participants medical records will be reviewed 1 year after surgery; however,
           participants will not need to have further study visits at this time.
    

Detailed Description

      BACKGROUND:

        -  The five-year survival rate for head and neck squamous cell carcinoma (HNSCC) has
           remained at approximately 50% for more than three decades.

        -  In HNSCC, the AKT-mTOR-pS6 pathway is aberrantly activated and promotes tumorigenesis
           and metastasis.

        -  Rapamycin is the most extensively studied mTOR inhibitor for which therapeutic daily
           oral dose and schedule, pharmacologic levels in blood, and safety have been established.

        -  Inhibition of mTOR by rapamycin causes the rapid apoptotic death of HNSCC tumor
           xenografts and decreases the tumor burden and prolongs the survival of mice harboring
           early and advanced oral and skin SCC lesions in a variety of experimental cancer models.

        -  Preliminary evidence suggests that mTOR inhibitors cause tumor shrinkage and improved
           tumor margins in HNSCC patients.

      OBJECTIVES:

        -  The primary objectives are to evaluate the following for patients with HNSCC given
           rapamycin as neoadjuvant treatment prior to surgery or chemoradiation:

             -  Whether therapeutic activities of rapamycin lead to inhibition of mTOR complexes,
                mTORC1 and mTORC2, as assessed by the change in levels of pS6 and pAkt473 measured
                by immunohistochemistry (IHC) in tumor samples and by Western blotting in
                peripheral blood mononuclear cells (PBMCs) and reduce tumor cell proliferation, as
                judged by IHC for Ki-67 in tumor samples.

             -  Antitumor activity in terms of objective response.

        -  Secondary objectives include safety evaluation of rapamycin therapy, exploratory studies
           of possible effects of rapamycin on tumor size, dynamic CT perfusion, and FDG-PET; and
           evaluation of tumor proliferation, apoptosis, microvessel density, and molecular changes
           associated with these effects. Survival status, recurrence of disease, metastases, and
           adverse events/serious adverse events, including complications of wound healing, which
           are related to rapamycin therapy will also be assessed for 360 days after surgery or
           chemoradiation through medical record review.

      ELIGIBILITY:

        -  Males and females age 18 years and older

        -  Previously untreated HNSCC of the oral cavity or oropharynx

        -  Clinical stage II, III, or IVA disease without distant metastasis

        -  Definitive therapy to include surgical resection or chemoradiation for curative purposes

        -  Life expectancy greater than six months

      STUDY DESIGN:

        -  Pilot, single arm, open-label, interventional neoadjuvant clinical trial.

        -  Twenty one evaluable subjects will take rapamycin (sirolimus) orally once per day for 21
           days.

        -  Before and after dosing, the tumor will be photographed and biopsied, peripheral blood
           mononuclear cells (PBMCs) will be collected, and computed tomography and positron
           emission tomography scans will be performed.

        -  Surgical or chemoradiation treatment, which is being provided outside of this protocol,
           will be conducted after Day 28 and when rapamycin levels are less than or equal to 3
           nanograms per milliter.

        -  Subjects will be followed by medical record review for 360 days after surgery or
           chemoradiation to assess 1) survival, 2) recurrence of disease, 3) metastases, and 4)
           adverse events/serious adverse events that are related to rapamycin therapy, including
           complications of wound healing and infections due to immune compromise.

        -  Levels of pS6 and pAkt473 in tumor tissue and PBMCs and Ki-67 in tumor tissue before and
           after rapamycin therapy will be determined by immunohistochemistry and by Western
           blotting. Computed tomography (CT) and positron emission tomography (PET) scans of the
           head, neck, and chest region with and without contrast will be performed within 7 days
           prior to the first rapamycin administration. One day after the last administration of
           rapamycin the CT and PET scans (head and neck region only) with contrast will be
           repeated.

        -  A single stage design will be used based on response defined as > 25% tumor shrinkage. A
           Wilcoxon signed rank test will be used to compare levels of pS6, pAkt473, and Ki-67
           before and after rapamycin therapy. As part of secondary analysis, the number of
           subjects achieving a best response of complete response (CR), partial response (PR),
           stable disease (SD), or progressive disease (PD) according to Response Evaluation
           Criteria in Solid Tumors (RECIST) version 1.1 will also be summarized.
    

Study Phase

Phase 1/Phase 2

Study Type

Interventional


Primary Outcome

Percent (%) Change in Levels of pS6, pAKt473, and Ki-67


Condition

Mouth Neoplasms

Intervention

Sirolimus

Study Arms / Comparison Groups

 Sirolimus
Description:  Subjects will be treated with sirolimus 21 days

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

37

Start Date

August 2010

Completion Date

December 2015

Primary Completion Date

June 2015

Eligibility Criteria

        -  ELIGIBILITY CRITERIA:

        Males and females and members of any race or ethnic group who meet the eligibility criteria
        may participate in this trial.

        INCLUSION CRITERIA:

        Participants must meet all of the following inclusion criteria:

          1. Age 18 years and older

          2. Histologically confirmed previously untreated squamous cell carcinoma o f the oral
             cavity or oropharynx accessible for biopsy

          3. Clinical stage II, III, or IVA disease without distant metastasis, as defined by the
             American Joint Committee on Cancer Staging System, Seventh edition.

          4. Definitive therapy to include surgical resection or chemoradiation for curative
             purposes

          5. Life expectancy o f greater than 6 months

          6. Eastern Cooperative Oncology Group ( ECOG) performance status of 0 or 1

          7. Willing and able to provide written informed consent

        EXCLUSION CRITERIA:

        Participants who meet any of the following criteria are not eligible for enrollment:

          1. Surgical resection or chemoradiation of the HNSCC is contraindicated

          2. Prior head or neck squamous cell carcinoma within 5 years, except for previously
             treated skin cancer

          3. Received chemotherapy targeted monoclonal antibody therapy or investigational therapy
             within 30 days prior to enrollment

          4. Previous radiation therapy to the head or neck

          5. No measurable tumor remaining after prior biopsy or negative margins from prior biopsy

          6. Inadequate hematologic, renal or liver function within l4 days prior to the first
             rapamycin dosing visit, as defined by:

               1. Absolute neutrophil count less than 1.5 times 10 (9)/L

               2. CD4 count < 400 (to account for natural fluctuations in CD4 levels, participants
                  with at least one CD4 count (Bullet) 400 within 14 days prior to dosing will not
                  be excluded)

               3. Platelet count less than 100 times 10(9)/L

               4. Hemoglobin less than l0 g/dL (eligibility level for hemoglobin may be reached by
                  transfusion)

               5. AST, ALT or bilirubin greater than 1.5 times the upper limit of local lab normal
                  values

               6. Total cholesterol level greater than 350 mg/dL

               7. Triglyceride level greater than 400 mg/dL

               8. International Normalized Ratio (INR) greater than 1.5

               9. Serum creatinine greater than 1.5mg/dL

          7. Active hepatitis or HBV or HCV infection

          8. Women who are pregnant or lactating (female of child-bearing age must be abstinent or
             use a barrier type birth control method throughout the study)

          9. Presence of any contraindications to rapamycin therapy, including HlV-protease
             inhibitors and drugs or agents that are modulators of cytochrome P-450 3A4 (CYP3A4)
             and p-glycoprotein(P-gp)

         10. Hypersensitivity to rapamycin

        11 .Has received live vaccine (such as influenza nasal vaccine measles mumps, rubella, oral
        polio, B CG, yellow fever, varicella, or TY2la typhoid) in the past 30 days or has plans to
        take a live vaccine in the next 3 months

        12. Any cognitive impairment that limits the subject s or the subject s legally authorized
        representative s ability to understand the protocol, provide informed consent or assent, or
        to comply with the protocol procedures

        13.Unable or unwilling to comply with the requirements of the protocol
      

Gender

All

Ages

18 Years - 80 Years

Accepts Healthy Volunteers

No

Contacts

Janice S Lee, DDS, MD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT01195922

Organization ID

100180

Secondary IDs

10-D-0180

Responsible Party

Sponsor

Study Sponsor

National Institute of Dental and Craniofacial Research (NIDCR)


Study Sponsor

Janice S Lee, DDS, MD, Principal Investigator, National Institute of Dental and Craniofacial Research (NIDCR)


Verification Date

October 2017